Literature DB >> 19141614

Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Sharareh Emadi1, Srinath Kasturirangan, Min S Wang, Philip Schulz, Michael R Sierks.   

Abstract

Neuropathologic and genetics studies as well as transgenic animal models have provided strong evidence linking misfolding and aggregation of alpha-synuclein to the progression of Parkinson disease (PD) and other related disorders. A growing body of evidence implicates various oligomeric forms of alpha-synuclein as the toxic species responsible for neurodegeneration and neuronal cell death. Although numerous different oligomeric forms of alpha-synuclein have been identified in vitro, it is not known which forms are involved in PD or how, when, and where different forms contribute to the progression of PD. Reagents that can interact with specific aggregate forms of alpha-synuclein would be very useful not only as tools to study how different aggregate forms affect cell function, but also as potential diagnostic and therapeutic agents for PD. Here we show that a single chain antibody fragment (syn-10H scFv) isolated from a phage display antibody library binds to a larger, later stage oligomeric form of alpha-synuclein than a previously reported oligomeric specific scFv isolated in our laboratory. The scFv described here inhibits aggregation of alpha-synuclein in vitro, blocks extracellular alpha-synuclein-induced toxicity in both undifferentiated and differentiated human neuroblastoma cell lines (SH-SY5Y), and specifically recognizes naturally occurring aggregates in PD but not in healthy human brain tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141614      PMCID: PMC2670110          DOI: 10.1074/jbc.M806559200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein.

Authors:  J Y Sung; J Kim; S R Paik; J H Park; Y S Ahn; K C Chung
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

2.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; M Hasegawa; M Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.

Authors:  M Hashimoto; E Rockenstein; M Mante; M Mallory; E Masliah
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

4.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

5.  Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein.

Authors:  Natalie Golts; Heather Snyder; Mark Frasier; Catherine Theisler; Peter Choi; Benjamin Wolozin
Journal:  J Biol Chem       Date:  2002-02-15       Impact factor: 5.157

6.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

Review 7.  Pathogenesis of Parkinson's disease.

Authors:  A H Schapira
Journal:  Baillieres Clin Neurol       Date:  1997-04

8.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.

Authors:  Tomas T Ding; Seung-Jae Lee; Jean-Christophe Rochet; Peter T Lansbury
Journal:  Biochemistry       Date:  2002-08-13       Impact factor: 3.162

9.  Neurodegenerative disease: amyloid pores from pathogenic mutations.

Authors:  Hilal A Lashuel; Dean Hartley; Benjamin M Petre; Thomas Walz; Peter T Lansbury
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

10.  Characterizing antibody specificity to different protein morphologies by AFM.

Authors:  Min S Wang; Andleeb Zameer; Sharareh Emadi; Michael R Sierks
Journal:  Langmuir       Date:  2009-01-20       Impact factor: 3.882

View more
  42 in total

1.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 2.  Progress in phage display: evolution of the technique and its application.

Authors:  Tomaz Bratkovic
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

3.  CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury.

Authors:  Stephanie M Williams; Carrie Peltz; Kristine Yaffe; Philip Schulz; Michael R Sierks
Journal:  Neurology       Date:  2018-10-09       Impact factor: 9.910

4.  Engineered antibody therapies coming of age for aging brains.

Authors:  Anne Messer
Journal:  Mol Ther       Date:  2014-10       Impact factor: 11.454

5.  Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis.

Authors:  Stephanie M Williams; Lalitha Venkataraman; Huilai Tian; Galam Khan; Brent T Harris; Michael R Sierks
Journal:  J Vis Exp       Date:  2015-02-12       Impact factor: 1.355

Review 6.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 7.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

8.  Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

Authors:  Min S Wang; Shanta Boddapati; Sharareh Emadi; Michael R Sierks
Journal:  BMC Neurosci       Date:  2010-04-30       Impact factor: 3.288

Review 9.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

10.  Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.

Authors:  Srinath Kasturirangan; Tim Reasoner; Philip Schulz; Shanta Boddapati; Sharareh Emadi; Jon Valla; Michael R Sierks
Journal:  Biotechnol Prog       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.